Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Share on StockTwits

Brainstorm Cell Therapeutics (NASDAQ:BCLI) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.12), Bloomberg Earnings reports.

Brainstorm Cell Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, hitting $3.71. 229 shares of the company were exchanged, compared to its average volume of 91,868. The company has a debt-to-equity ratio of 9.34, a quick ratio of 0.97 and a current ratio of 0.97. The firm has a 50 day moving average price of $3.99. Brainstorm Cell Therapeutics has a 12-month low of $2.92 and a 12-month high of $4.50.

Several research firms have weighed in on BCLI. Maxim Group reissued a “buy” rating and set a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, May 14th. ValuEngine downgraded Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd.

A number of institutional investors have recently added to or reduced their stakes in BCLI. Delek Group Ltd. acquired a new stake in shares of Brainstorm Cell Therapeutics during the first quarter worth $183,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Brainstorm Cell Therapeutics by 349.9% during the first quarter. CIBC Private Wealth Group LLC now owns 67,484 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 52,484 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Brainstorm Cell Therapeutics by 44.6% during the second quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 40,197 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Brainstorm Cell Therapeutics by 10.7% during the second quarter. Renaissance Technologies LLC now owns 224,377 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 21,720 shares during the last quarter. 10.71% of the stock is owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Further Reading: Certificate of Deposit (CD)

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.